NRx Pharmaceuticals, Inc.
NRXP
Rank in Stocks
#19533
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on... NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Share Price
$2.38
Last synced: 2026-11-09
Market Cap
$103.04M
Change (1 day)
0.00%
Change (1 year)
-8.11%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade NRx Pharmaceuticals, Inc. (NRXP)
Category
Healthcare
EPS for NRx Pharmaceuticals, Inc. (NRXP)
EPS as of June 2026 TTM: $-0.74
According to NRx Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-0.74. At the end of 2025 the company had an EPS of $-1.34, an increase over its 2024 EPS of $-2.39.
EPS history for NRx Pharmaceuticals, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.74 | -44.78% |
| 2025 | $-1.34 | -43.93% |
| 2024 | $-2.39 | -39.95% |
| 2023 | $-3.98 | 563.33% |
| 2022 | $-0.60 | -91.94% |
| 2021 | $-7.44 | 392.72% |
| 2020 | $-1.51 | -288.75% |
| 2019 | $0.80 | 979.62% |
| 2018 | $0.07 | -161.75% |
| 2017 | $-0.12 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,216.22% |
US
|
|
| $-7.07 | 855.41% |
US
|
|
| $-5.29 | 614.86% |
AU
|
|
| $12.88 | -1,840.55% |
BE
|
|
| $21.56 | -3,013.51% |
NL
|
Questions about NRx Pharmaceuticals, Inc.'s earnings per share (EPS)
What is NRx Pharmaceuticals, Inc.'s earnings per share (EPS)?
NRx Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-0.74, as of Jun 2026.
What was NRx Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, NRx Pharmaceuticals, Inc.'s earnings per share (EPS) was $-1.34, compared with $-2.39 in 2024.
How has NRx Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, NRx Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2022 ($-0.60) and lowest in 2021 ($-7.44).
How does NRx Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
NRx Pharmaceuticals, Inc.'s earnings per share (EPS) ($-0.74) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.